Núñez Abad, M.; Calabuig-Fariñas, S.; Lobo de Mena, M.; Torres-Martínez, S.; García González, C.; García García, J.Á.; Iranzo González-Cruz, V.; Camps Herrero, C.
Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer. Cancers 2022, 14, 307.
https://doi.org/10.3390/cancers14020307
AMA Style
Núñez Abad M, Calabuig-Fariñas S, Lobo de Mena M, Torres-Martínez S, García González C, García García JÁ, Iranzo González-Cruz V, Camps Herrero C.
Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer. Cancers. 2022; 14(2):307.
https://doi.org/10.3390/cancers14020307
Chicago/Turabian Style
Núñez Abad, Martín, Silvia Calabuig-Fariñas, Miriam Lobo de Mena, Susana Torres-Martínez, Clara García González, José Ángel García García, Vega Iranzo González-Cruz, and Carlos Camps Herrero.
2022. "Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer" Cancers 14, no. 2: 307.
https://doi.org/10.3390/cancers14020307
APA Style
Núñez Abad, M., Calabuig-Fariñas, S., Lobo de Mena, M., Torres-Martínez, S., García González, C., García García, J. Á., Iranzo González-Cruz, V., & Camps Herrero, C.
(2022). Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer. Cancers, 14(2), 307.
https://doi.org/10.3390/cancers14020307